Kyndryl Holdings, Inc. (KD) Class Action Lawsuit Seeks Recovery for Investors; April 13, 2026, Deadline - Contact Kessler Topaz Meltzer & Check, LLP [Accessibility Statement] Skip NavigationDid you buy KD securities between August 7, 2024, and February 9, 2026?Affected Kyndryl Holdings, Inc. Investor Summary- Investor Action: Contact [Kessler Topaz Meltzer & Check, LLP (www.ktmc.com)] for recovery options at no cost to investor- Key Lawsuit Allegations: Material misstatements and/or omissions concerning the ...

Core Viewpoint - The Gross Law Firm has announced a class action lawsuit against BlackRock TCP Capital Corp. (NASDAQ: TCPC) for allegedly issuing misleading statements regarding the company's investments and financial health during the class period from November 6, 2024, to January 23, 2026 [1]. Group 1: Allegations - The complaint alleges that TCPC's investments were not being timely or appropriately valued [1]. - It is claimed that the company's portfolio restructuring efforts were ineffective in resolving challenged credits or improving portfolio quality [1]. - The lawsuit asserts that TCPC's unrealized losses were understated, leading to an overstated net asset value [1]. - As a result of these issues, the positive statements made by the defendants about the company's business and prospects were materially misleading [1]. Group 2: Class Action Details - Shareholders who purchased TCPC shares during the specified class period are encouraged to contact the Gross Law Firm for potential lead plaintiff appointment [1]. - The deadline for shareholders to register for the class action is April 6, 2026 [1]. - Participants will be enrolled in a portfolio monitoring software to receive updates throughout the case lifecycle [1].

Picard Medical, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm for More Information - PMI [Accessibility Statement] Skip NavigationNEW YORK, Feb. 19, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Picard Medical, Inc. (NYSE: PMI).Shareholders who purchased shares of PMI during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to ...

Shareholders that lost money on Vistagen Therapeutics, Inc.(VTGN) Urged to Join Class Action - Contact The Gross Law Firm to Learn More [Accessibility Statement] Skip NavigationNEW YORK, Feb. 19, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Vistagen Therapeutics, Inc. (NASDAQ: VTGN).Shareholders who purchased shares of VTGN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff i ...

Core Viewpoint - Ramaco Resources, Inc. is facing a class action lawsuit due to allegations of issuing materially false and misleading statements regarding its mining activities at the Brook Mine during the class period from July 31, 2025, to October 23, 2025 [1] Group 1: Allegations - The lawsuit claims that Ramaco did not commence any significant mining activity at the Brook Mine after groundbreaking [1] - It is alleged that no active work was taking place at the Brook Mine, leading to an overstatement of development progress [1] - The positive statements made by the company about its business, operations, and prospects were materially misleading and lacked a reasonable basis [1] Group 2: Class Action Details - The deadline for shareholders to register for the class action and seek lead plaintiff status is March 31, 2026 [1] - Shareholders who purchased shares of METC during the specified class period are encouraged to contact the Gross Law Firm for potential lead plaintiff appointment [1] - Participation in the case does not require appointment as lead plaintiff, and there is no cost or obligation to participate [1]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of Ultragenyx Pharmaceutical Inc. during the specified class period of the upcoming lead plaintiff deadline for a class action lawsuit [1]. Group 1: Class Action Details - Investors who bought Ultragenyx common stock between August 3, 2023, and December 26, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by April 6, 2026 [3]. Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements, including the largest securities class action settlement against a Chinese company [4]. - The firm has consistently ranked among the top firms for securities class action settlements, recovering hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4]. Group 3: Case Background - The lawsuit alleges that Ultragenyx's defendants provided misleading information regarding the expected results of its Phase III studies for setrusumab (UX 143) in treating Osteogenesis Imperfecta [5]. - It is claimed that while setrusumab increased bone density, it did not correlate with a decrease in annualized fracture rates, contrary to the positive statements made by the defendants [6].

Core Viewpoint - A class action lawsuit has been filed against Mereo BioPharma Group plc, alleging securities fraud and unlawful business practices by the company and certain officers and/or directors [2]. Group 1: Lawsuit Details - Investors are encouraged to contact Pomerantz LLP for participation in the class action, with a deadline to apply as Lead Plaintiff by April 6, 2026 [2]. - A copy of the Complaint related to the class action can be accessed at Pomerantz's website [2]. Group 2: Company Performance and Stock Impact - On July 9, 2025, Mereo and Ultragenyx Pharmaceutical Inc. announced that the Phase 3 Orbit study was progressing towards a final analysis, leading to a significant drop in Mereo's ADR price by $1.25, or 42.52%, closing at $1.69 on July 10, 2025 [4]. - On December 29, 2025, Mereo reported that neither the Orbit nor the Cosmic Phase 3 studies achieved statistical significance, resulting in a drastic decline in ADR price by $2.02, or 87.7%, closing at $0.29 [5].

Ultragenyx Pharmaceutical (NASDAQ:RARE) is one of the 17 biotechnology stocks with more than 50% upside. On February 3, the price target on Ultragenyx Pharmaceutical (NASDAQ:RARE) was set to $60 by H.C. Wainwright analyst Ram Selvaraju, who maintained a Buy rating on the stock. The analyst’s estimate leads to a promising upside potential of more than 155% from the prevailing level. Adaptive Biotechnologies (ADPT) Hits 3-Year High. Here's Why Pressmaster/Shutterstock.com Selvaraju attributed his views t ...

Core Viewpoint - A class action lawsuit has been filed against Ultragenyx Pharmaceutical Inc. for allegedly providing misleading information regarding the efficacy of its drug setrusumab during clinical trials, leading to inflated stock prices for investors [1][5][6]. Group 1: Lawsuit Details - The class action lawsuit is on behalf of purchasers of Ultragenyx common stock between August 3, 2023, and December 26, 2025 [1]. - The lawsuit claims that Ultragenyx's management made overly positive statements about setrusumab's ability to reduce fracture rates in Osteogenesis Imperfecta patients while concealing material adverse facts [5][6]. - It is alleged that the Phase III studies were less likely to demonstrate the claimed efficacy than management suggested, resulting in investors purchasing shares at artificially inflated prices [6]. Group 2: Legal Representation - Investors who purchased Ultragenyx stock during the class period may be entitled to compensation without upfront costs through a contingency fee arrangement [2]. - To join the class action, investors can visit the provided link or contact the law firm directly for more information [3][7]. - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4].

Core Viewpoint - A class action lawsuit has been filed against Ultragenyx Pharmaceutical Inc. for allegedly providing misleading information regarding the efficacy of its drug setrusumab during clinical trials, leading to inflated stock prices for investors who purchased shares between August 3, 2023, and December 26, 2025 [1][5][6]. Group 1: Lawsuit Details - The lawsuit claims that Ultragenyx's management made overly positive statements about setrusumab's ability to reduce fracture rates in Osteogenesis Imperfecta patients while concealing material adverse facts about the drug's actual efficacy [5][6]. - It is alleged that the Phase III Orbit and Cosmic studies were less likely to demonstrate the claimed benefits than management suggested, which misled investors [6]. Group 2: Investor Information - Investors who purchased Ultragenyx common stock during the class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To participate in the class action, investors can visit the provided link or contact the law firm for more information [3][7]. Group 3: Law Firm Credentials - The Rosen Law Firm, which is leading the class action, has a strong track record in securities class actions, having achieved significant settlements for investors, including over $438 million in 2019 [4]. - The firm has been recognized for its success in securities class action settlements and has a history of representing investors globally [4].